First Berlin Equity Research GmbH’s Post

Last week at the Private Equity Insights conference in Munich, we had productive discussions about the current market landscape. The key takeaway? Private equity investors continue to focus more on operational support and creating liquidity to remain competitive in fundraising. Here are my three key takeaways from the event: 1. Continuation funds are the hot topic at the moment. The holding period is increasing significantly, as either the exit markets are currently not favorable or the assets are not ready to sell. Many market participants also still see enormous growth potential in their assets, which is why a current exit is not an option. As the focus is nevertheless on creating liquidity, GP and LP led secondaries are increasing significantly. 2. Specialist funds are benefiting from the fact that liquidity is tight on the LP side, leading to a shift away from standard funds towards more niche strategies. 3. Regarding deal sourcing, which aligns with my area of focus, the issue is not a lack of opportunities but rather the challenge of filtering high-quality deals from the rest. While maintaining regular communication and a clear focus is essential, leveraging digital tools like platforms and systems can greatly enhance efficiency.

Private Equity Investments sind eine attraktive Möglichkeit, in nicht börsennotierte Unternehmen zu investieren, und der Small-Cap-Sektor bietet besondere Chancen. Diversifizierte Private Equity Fund Portfolios im Small-Cap-Bereich haben mehrere Vorteile, die Investoren ansprechen sollten. Erfahren Sie mehr über die wichtigsten Vorteile dieser Fundklasse. #SMEAdvisors, #Growth, #SMEGrowth, #SMEGrowthFunds, #Privateequity, #PEfunds, #Privatedebt, #catgrowth, #pmeconsults, #growthfinancing, #KMUFinanzierung , #Wachstumsfinanzierung, #Nachfolgefinanzierung, #privatemarkets , #impactinvesting Martin Ziehbrunner Andreas Schimanski Peter Koller Christoph Krammer Beat Saurer Dominik Probst Dominik Habermacher Marc Z. Simon Frei Gabriela Loepfe-Lazar Mario Solenicki Jonas Greminger Raphael Ledergerber David Klee Andre Grethler Hans-Peter Kellenberger Mike Bürgler Mariana Ziehbrunner-Petrache

Im Small Cap Bereich sind die Firmenbewertungen wieder auf einem interessanten Niveau angekommen und bieten gute Möglichkeiten für einen Einstieg. Bei den SME Growth Funds können die im Paper beschriebenen Vorteile erreicht werden.

Are you looking to learn more on how to secure funding & navigate the deal-making process successfully? Register below for California Life Sciences (CLS) next Access to Capital webinar series!

I love this biotech investing framework from Erez Kalir. Here’s his simple yet highly effective process, which he discussed on a recent episode of the Stansberry Investor Hour: 1. The science 2. The opportunity—sizing the addressable market and performing an expected value analysis 3. The capitalization (cap) table—list of the company’s largest shareholders divided into 3 subcategories: insiders, the “smart money” (short list of the most accomplished biotech investors in the world, and the “whales” (large financial institutions or big pharma that have a big stake in the company) 4. The balance sheet 5. The catalysts 6. The big picture and how it impacts the opportunity 7. The overall risk/reward As Kalir explained, not every element of a framework is equally applicable to every situation. Depending on the market’s context, some components are far more valuable than others. His full interview is worth a listen, but he starts discussing his process at the 30:50 mark.

Private Equity Investments sind eine attraktive Möglichkeit, in nicht börsennotierte Unternehmen zu investieren, und der Small-Cap-Sektor bietet besondere Chancen. Diversifizierte Private Equity Fund Portfolios im Small-Cap-Bereich haben mehrere Vorteile, die Investoren ansprechen sollten. Erfahren Sie mehr über die wichtigsten Vorteile dieser Fundklasse. #SMEAdvisors, #Growth, #SMEGrowth, #SMEGrowthFunds, #Privateequity, #PEfunds, #Privatedebt, #catgrowth, #pmeconsults, #growthfinancing, #KMUFinanzierung , #Wachstumsfinanzierung, #Nachfolgefinanzierung, #privatemarkets , #impactinvesting Martin Ziehbrunner Andreas Schimanski Peter Koller Christoph Krammer Beat Saurer Dominik Probst Dominik Habermacher Marc Z. Simon Frei Gabriela Loepfe-Lazar Mario Solenicki Jonas Greminger Raphael Ledergerber David Klee Andre Grethler  Hans-Peter Kellenberger Mike Bürgler Mariana Ziehbrunner-Petrache

Die #KEPLER Investment-Philosophie bei Anleihen: #Anleihen managen wir aus einem anderen Blickwinkel. Weil wir dabei auch in Nischen-Segmenten Ertragspotenziale heben. #fonds #keplerfonds #investment #investieren #marketing #geldanlage

Attention publishing colleagues responsible for brand, research, and legal integrity and risk management. Saying that you should get in touch with us without saying you should get in touch..? Outsell writes: "When it comes to facing the growing research integrity crisis, Morressier has scooped the competition", Protecting Research Integrity: Critical Investments and Innovations for 2023 https://lnkd.in/eCpZqjrj Morressier announces $16.5m Series B to lead the fight for research integrity https://lnkd.in/e9Hy2c-u Morressier announces partnership with Clear Skies to bring paper-mill detection to submission workflows https://lnkd.in/esyBsmPf IOP Publishing and Morressier partner to develop a state-of-the-art submission and peer review system https://lnkd.in/emRV32Zr neil.christensen@morressier.com #researchintegrity

🔍 Welche mittelfristigen Trends gibt es im Nebenwerte-Segment? Miguel Lago Mascato, Senior Equity Analyst, teilt seine spannenden Einblicke im Interview. Erfahrt mehr über die Zukunft dieser dynamischen Märkte! 🧠✨ #ResearchExcellence #MontegaAG #FinanceInsights #MontegaShorts #Investmentbanking #aktien #nebenwerte #assetmanagement #investorrelations #ir

California Life Sciences (CLS) is excited to announce the next installment of our Access to Capital webinar series, in collaboration with Hogan Lovells, "What’s the Deal with Due Diligence?" In the world of life sciences, understanding the intricacies of due diligence is crucial for emerging companies looking to secure funding and navigate the deal-making process successfully. This webinar will provide invaluable insights from Sally Gu, Jessica Hanna, Spenser Karr and Eva M. Schifini who will share their corporate and regulatory perspectives. Whether you're a startup founder, an executive in the life sciences field, or an investor looking to understand the nuances of due diligence, this webinar is designed for you! Don't miss out on the opportunity to equip yourself with the tools you need to navigate the complexities of dealmaking in the life sciences. We look forward to seeing you there! Register here: https://bit.ly/3TqzD7M #LifeSciences #DueDiligence #AccessToCapital #CLS #HoganLovells #EmergingCompanies #Investment #Funding #Innovation